An act to amend Section 1342.74 of the Health and Safety Code, and to amend Section 753 10123.1933 of the Insurance Code, relating to insurance. health care coverage.
SB 1023 expands California’s existing coverage rules for HIV prevention medications and related products. Under current law, health care service plans and health insurers may not impose prior authorization or step therapy on medically necessary antiretroviral drugs used for HIV/AIDS prevention, including PrEP and PEP. This bill broadens that protection to include antiretroviral drug devices and drug products, not just drugs, and keeps the prohibition on prior authorization and step therapy for those prevention items.
The bill also adds a new coverage requirement for certain non-self-administered FDA-approved HIV prevention products. For health plan contracts and health insurance policies issued, amended, or renewed on or after January 1, 2027, if the product is covered as a medical benefit, it must also be covered as an outpatient prescription drug benefit. The measure continues to require coverage and reimbursement for PrEP and PEP furnished by pharmacists, including related testing and pharmacist services, and it bars plans and pharmacy benefit managers from preventing pharmacies from dispensing these medications. It excludes specialized dental, vision, and mental health plans, Medicare supplement contracts, and Medi-Cal managed care plans to the extent coverage is excluded under their state contracts.
In addition to the health coverage provisions, the bill makes technical, nonsubstantive changes to Insurance Code provisions governing unlawful financial benefits, including rules that prohibit insurance agents and brokers from receiving compensation or other benefits for steering insureds to auto repair facilities. The bill also states that no state reimbursement is required for local agencies or school districts because any costs would arise only from changes to criminal provisions.
The overall sentiment reflected in the available legislative history is favorable. The bill received unanimous support in committee votes shown in the record, including a 9-0 do pass vote and a later 7-0 vote to place it on suspense file. That pattern suggests broad agreement with the bill’s public health goals and its insurance coverage expansions, even though it still moved through the appropriations process.
The main policy focus is access to HIV prevention care, especially reducing administrative barriers and ensuring coverage parity for newer non-self-administered products. The likely points of contention are limited in the record provided, but the bill’s expansion of mandated coverage could raise concerns for insurers about utilization management, benefit design, and cost. The suspense-file referral also indicates that fiscal impacts, rather than policy opposition, may have been the primary issue under review.
SB 1023 would amend the Knox-Keene Act and the Insurance Code to expand mandated coverage for HIV prevention products in California. It would prohibit health care service plans and health insurers from using prior authorization or step therapy for medically necessary antiretroviral drugs, drug devices, and drug products used to prevent HIV/AIDS, and it would require certain plans and policies to cover qualifying non-self-administered FDA-approved HIV prevention products as both a medical benefit and an outpatient prescription drug benefit starting with policies issued, amended, or renewed on or after January 1, 2027. It also preserves and reinforces existing pharmacist-dispensing and reimbursement requirements for PrEP and PEP, while excluding specified specialized plans, Medicare supplement contracts, and Medi-Cal managed care plans where coverage is otherwise excluded. Separately, it makes technical, nonsubstantive changes to Insurance Code provisions on unlawful financial benefits involving auto repair referrals.
The available legislative record suggests generally supportive sentiment toward the bill. Committee votes were unanimous in the actions provided, indicating no recorded opposition at those stages. The bill’s focus on HIV prevention access, pharmacist dispensing, and reducing utilization-management barriers appears to have broad policy appeal, though it was still placed on the suspense file, which suggests fiscal or administrative scrutiny rather than substantive opposition.
The main substantive issue is whether insurers and health plans should be required to cover a broader set of HIV prevention products without prior authorization or step therapy, and whether non-self-administered products should be covered in both medical and pharmacy benefit categories. Insurers may be concerned about added costs, benefit duplication, and administrative complexity, while advocates are likely focused on access, continuity of care, and eliminating barriers to PrEP and PEP. The suspense-file placement suggests the appropriations impact may have been the most notable point of review, even though the recorded votes show no direct opposition.